{
    "clinical_study": {
        "@rank": "112681", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: HT-100 tablet, Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "\u2022     Multiple dose administration: Dose 1"
            }, 
            {
                "arm_group_label": "Cohort 2: HT-100 tablet, Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "\u2022     Multiple dose administration: Dose 2"
            }, 
            {
                "arm_group_label": "Cohort 3: HT-100 tablet, Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "\u2022     Multiple dose administration: Dose 3"
            }, 
            {
                "arm_group_label": "Cohort 4: HT-100 tablet, Dose 4", 
                "arm_group_type": "Experimental", 
                "description": "\u2022     Multiple dose administration: Dose 4"
            }, 
            {
                "arm_group_label": "Cohort 5: HT-100 tablet, Dose 5", 
                "arm_group_type": "Experimental", 
                "description": "\u2022     Multiple dose administration: Dose 5"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to provide 6-months continuous dosing with the study medication,\n      called HT-100, on participants who successfully completed the predecessor study\n      (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability,\n      pharmacodynamic activity (testing the drug's effect on DMD) and population pharmacokinetics\n      (measuring how much drug is in the bloodstream) in participants with a broad spectrum of\n      Duchenne muscular dystrophy (DMD)."
        }, 
        "brief_title": "Open Label Extension Study of HT-100 in Patients With DMD", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Duchenne Muscular Dystrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Dystrophy, Duchenne", 
                "Muscular Dystrophies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completed both the single ascending dose (SAD) and multiple ascending dose (MAD)\n             phases of predecessor study HALO-DMD-01\n\n          -  Maintained the same corticosteroid therapy  from the predecessor study HALO-DMD-01\n\n          -  Ability to provide written informed consent\n\n          -  Ambulatory or non-ambulatory\n\n        Exclusion Criteria:\n\n          -  Recent, substantial change in use of cardiac medications or medications affecting\n             muscle function\n\n          -  Clinically significant major disease, not related to DMD\n\n          -  Significantly compromised cardio-respiratory function\n\n          -  History of severe allergic or anaphylactic reactions\n\n          -  Prior treatment with another investigational product in past 6 months\n\n          -  Inability to undergo magnetic resonance imaging (MRI)\n\n          -  Current drug or alcohol abuse or prior treatment for abuse"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978366", 
            "org_study_id": "HALO-DMD-02", 
            "secondary_id": "HALO   [Halo Therapeutics]"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1: HT-100 tablet, Dose 1", 
                "Cohort 2: HT-100 tablet, Dose 2", 
                "Cohort 3: HT-100 tablet, Dose 3", 
                "Cohort 4: HT-100 tablet, Dose 4", 
                "Cohort 5: HT-100 tablet, Dose 5"
            ], 
            "intervention_name": "HT-100", 
            "intervention_type": "Drug", 
            "other_name": "halofuginone hydrobromide delayed-release tablet"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protein Synthesis Inhibitors", 
                "Halofuginone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Duchenne muscular dystrophy", 
            "halofuginone hydrobromide", 
            "anti-fibrotic", 
            "anti-inflammatory", 
            "muscle regeneration", 
            "protein synthesis inhibitor"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "link": {
            "description": "Sponsor company website", 
            "url": "http://www.halotherapeutics.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California, Davis Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Kennedy Krieger Institute, Johns Hopkins School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43205"
                    }, 
                    "name": "Nationwide Children's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01", 
        "overall_official": {
            "affiliation": "Halo Therapeutics", 
            "last_name": "Diana M Escolar, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Target Safety profile by review of adverse events (AEs)\nPhysical examination findings\nClinical laboratory test results\nOther diagnostic testing", 
            "measure": "Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.", 
            "safety_issue": "Yes", 
            "time_frame": "Months 2, 4, 6, 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978366"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pulmonary function\nMotor function\nMuscle composition\nBiochemical and imaging markers", 
                "measure": "Pharmacodynamic signals of HT-100 following chronic oral administration of multiple doses to boys with DMD.", 
                "safety_issue": "No", 
                "time_frame": "Months 4, 6, 7"
            }, 
            {
                "description": "Halofuginone plasma concentrations", 
                "measure": "Pharmacokinetic plasma profile of HT-100 following chronic oral administration of multiple doses to boys with DMD.", 
                "safety_issue": "Yes", 
                "time_frame": "Months 4, 6"
            }
        ], 
        "source": "Halo Therapeutics, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Halo Therapeutics, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013", 
        "why_stopped": "FDA placed the protocol on clinical hold while new data are evaluated. Enrolled subjects are\n    not taking HT-100. Clinic visits are continuing per protocol."
    }
}